A new breast cancer drug improves overall survival among people with brain and other metastases
https://www.facingourrisk.org/XRAY/new-drug-improves-outcomes-for-metastatic-breast-cancer
A promising new drug called tucatinib combined with standard therapy shows benefit for women with HER2-positive metastatic breast cancer. Women who took tucatinib experienced longer progression-free survival (time before their cancer worsened), longer overall survival time and response of cancer (shrinking or disappearing). Strikingly, better outcomes were also seen for women with brain metastases, which is often difficult to treat. (12/20/19)
THIS INFORMATION HAS BEEN UPDATED on 04/17/20: The U.S. Food and Drug Administration has approved Tukysa (tucatinib) for use in combination with trastuzumab (Herceptin) and capecitabine for patients with advanced or metastatic HER2-positive breast cancer, including patients with brain metastases (disease that has spread to the brain). Patients who have received one or more treatments targeting Her2 in the metastic setting are eligible to receive Tukysa. Tukysa is an oral (tablet) tyrosine kinase inhibitor which is taken twice daily.
Questions To Ask Your Health Care Provider
- Is my breast cancer HER2-positive or HER2-negative?
- What is the best treatment for my metastatic breast cancer?
- Are there any new treatments that are available to treat my metastatic breast cancer?
- Do I qualify for any clinical trials that are enrolling participants?
Open Clinical Trials
The following studies look at treatment for people with metastatic HER2-positive breast cancer.
- NCT05458674: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC. This study evaluates the safety and efficacy of the three-drug combination of tucatinib, trastuzumab and eribulin in patients with unresectable metastatic HER2-positive breast cancer after prior treatment with a taxane, trastuzumab and T-DM1.
- NCT06100874: A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN). This study evaluates the safety and effectiveness of sacituzumab govitecan with trastuzumab (Herceptin, Herceptin Hylecta, or trastuzumab biosimilar) in metastatic HER2+ breast cancer.
- NCT03368729: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer. This study evaluates the safety and tolerability of the PARP inhibitor niraparib combined with anti-HER2 agent trastuzumab for patients with metastatic HER2-positive breast cancer.
- NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer. This study evaluates the safety and effectiveness of zanidatamab combined with chemotherapy compared to trastuzumab (Herceptin) combined with chemotherapy to treat participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous T-DXd treatment.
- NCT05378464: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer. This study tests the safety of Adoptive T-Cell therapy following the Dendritic Cell (DC1) vaccine given in combination with pepinemab added to standard-of-care therapy trastuzumab for people with HER2-positive breast cancer.
- NCT05894239: A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer. This study looks at the safety and effectiveness of inavolisib combined with Phesgo (pertuzumab, trastuzumab and rHuPH20 injection) compared with placebo combined with Phesgo for maintenance therapy after induction therapy for participants with previously untreated HER2-positive advanced breast cancer (ABC).
Other clinical trials for people with breast cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.